For pharmaceutical and health brands, packaging has a much bigger role than presentation. Once a product has been manufactured, the work involved in preparing it for the Australian market can include labelling, batch and expiry coding, inserting product information, repacking and other secondary packaging processes.
These steps need to be carried out accurately because a mistake at this stage can affect traceability, delay product release or require stock to be reworked. For brands managing valuable inventory and strict supply timelines, a packaging problem close to the end of the process can have consequences well beyond the cost of replacing a label or carton.
That makes pharmaceutical secondary packaging an important part of the wider manufacturing and supply process. Choosing a provider with suitable systems, experience and regulatory capabilities can help brands maintain control while getting products ready for distribution.
What Is Secondary Packaging in Pharmaceuticals?
Primary packaging is the material that directly contains the product, such as a blister, bottle or vial. Secondary packaging takes place without opening or altering that primary container and can include cartons, labels, information inserts and other components used to prepare the finished product for supply.
Depending on the product and project, secondary packaging may involve activities such as relabelling, repacking, batch and expiry coding, inserting information materials or changing the number of primary packs contained within an outer pack.
Although these activities happen towards the end of the manufacturing process, they still require careful control. The product may already represent a substantial investment by the time it reaches secondary packaging, so an error at this stage can place an entire batch at risk of delay or rework.
Accurate Labelling Supports Traceability
Labels carry information that helps identify and trace a product throughout the supply chain. Batch numbers, expiry dates and other approved information need to correspond with the correct stock and remain legible throughout handling and distribution.
This becomes particularly important when several batches, pack sizes or product variations are being handled at the same time. A strong pharmaceutical packaging process should include controls that reduce the risk of components being mixed between production runs.
Traceability is also critical if an issue needs to be investigated later. Clear records help establish which materials were used, which batch was packed and what happened during each stage of the process.
Batch and Expiry Coding Needs to Be Right the First Time
Batch and expiry coding may appear to be a relatively straightforward part of packaging, but errors can create significant operational problems.
Incorrect, unreadable or misplaced coding can result in stock being held while the issue is investigated. Depending on the circumstances, products may need to be inspected, relabelled or reworked before they can continue through the supply chain.
For pharmaceutical and health brands, the cost is rarely limited to the physical correction. Delayed stock can affect distribution schedules, retailer commitments and inventory planning. Accurate coding from the outset helps reduce these disruptions and supports reliable product identification.
Re-Labelling and Repacking Require Controlled Processes
There are many legitimate reasons why therapeutic goods may need to be relabelled or repacked. Packaging artwork may change, approved information may be updated, imported stock may require changes for the Australian market, or an existing pack may need to be reconfigured.
When this happens, the work needs to be carefully controlled. Old and new packaging components must be managed correctly, completed quantities need to be reconciled and affected products must remain traceable throughout the process.
For brands holding large quantities of usable stock, controlled relabelling services or repacking can also help avoid unnecessary write-offs. Correcting the secondary packaging can provide a practical alternative when the underlying product remains suitable but the external packaging needs to change.
Documentation Matters as Much as the Physical Packaging
A completed carton may look correct from the outside, but pharmaceutical secondary packaging also depends on what has been recorded behind the scenes.
Packaging documentation can provide evidence of what was received, what was used, what was produced and what happened to unused or rejected materials. This creates a clear production history and helps discrepancies be investigated quickly.
Integrated management systems in co-packing can also improve visibility across production, inventory, quality assurance and compliance processes.
Good documentation also supports consistency. Rather than relying on individual staff members to remember how a job should be completed, approved procedures and specifications provide a repeatable process for future batches.
For pharmaceutical and health brands, this level of control becomes increasingly important as product ranges, batch volumes and regulatory requirements become more complex.
Quality Control Should Continue Throughout the Job
Waiting until the end of a packaging run to identify a problem can turn a small mistake into a much larger rework project. Quality control in contract packaging should therefore form part of the process rather than being treated as a final inspection alone.
Checks may be required when materials are received, during line setup, throughout production and before finished stock moves to its next stage. This can help identify issues such as incorrect labels, coding errors, damaged packaging or component mix-ups before they affect a larger quantity of product.
Clear procedures are particularly valuable when similar products or packaging components are being handled within the same facility. Separating materials correctly and following controlled line clearance processes reduces the opportunity for errors between jobs.
Secondary Packaging Can Affect Release Timelines
For brands working to strict launch or replenishment dates, secondary packaging can become a critical point in the schedule. Production may be complete, but stock still cannot move forward until the remaining packaging, checking and documentation requirements have been satisfied.
This is why turnaround time needs to be considered alongside quality. A provider should be able to plan realistic production windows, account for the required controls and communicate quickly if something could affect the agreed schedule.
Trying to recover time by rushing the final packaging stages can create greater delays if errors then need to be corrected. Reliable planning is generally more valuable than an unrealistic promise of the fastest possible turnaround.
Release for Supply Adds Another Layer of Responsibility
For medicines subject to Australian GMP requirements, Release for Supply involves an authorised person confirming that a batch has been produced and controlled in accordance with the applicable requirements before it is supplied.
Secondary packaging can form part of this process. In some circumstances, medicines that have already been released and then undergo further relabelling or secondary packaging may require another Release for Supply step.
Brands therefore need to understand what manufacturing and release activities their project requires and whether the chosen provider holds the appropriate TGA licence and accreditation for those activities. Where secondary packaging and Release for Supply are coordinated within the same operation, it may also reduce unnecessary movement between separate facilities.
The important point is to establish responsibilities before stock arrives. Packaging, documentation, quality review and release requirements should be incorporated into the production plan rather than addressed separately at the end.
Poor Secondary Packaging Can Create Expensive Delays
Packaging errors often become expensive because they occur when the product is close to being ready for market. By this stage, manufacturing, freight, materials and inventory costs may already have been incurred.
A problem with a label, carton or batch code can then hold finished goods in storage while investigations or corrections take place. If the product was intended for a launch, promotion or retailer deadline, the commercial impact can increase quickly.
A controlled secondary packaging process reduces this exposure by identifying requirements early, using approved specifications and maintaining clear checks throughout production.
What Health and Pharmaceutical Brands Should Look for in a Packaging Partner
Pharmaceutical secondary packaging requires more than access to packing equipment. Brands need a provider whose processes suit the products being handled and the regulatory requirements that apply to the work.
Before appointing a partner, it is worth considering:
- appropriate TGA licensing for the required activities
- experience handling therapeutic goods
- documented quality assurance procedures
- accurate batch and expiry coding capabilities
- controlled labelling and relabelling processes
- batch and component reconciliation
- procedures for managing non-conforming products
- clear production and quality documentation
- realistic turnaround planning
- Release for Supply capability where required
The exact requirements will depend on the type of product and the work being performed, so brands should confirm what applies to their project rather than assuming the same regulatory framework covers every health product.
The provider should also be able to explain how its processes operate in practice. Clear answers around stock control, documentation and quality procedures are more valuable than broad assurances about attention to detail.
Secondary Packaging Is Part of the Wider Supply Chain
Packaging decisions can affect what happens after production. Finished goods may need to move into storage, fulfilment or distribution immediately after completion, so coordination between these functions can help avoid unnecessary handling and delays.
For brands outsourcing several parts of the process, working with a provider that can connect pharmaceutical packing with 3PL warehousing and logistics may simplify inventory management. Finished stock can move through a more coordinated workflow instead of being transferred between several unrelated suppliers.
This becomes particularly useful when volumes fluctuate or products need to reach different customers, distributors or retail channels.
Protecting Product Value at the Final Stages
By the time a pharmaceutical or health product reaches secondary packaging, considerable work has already gone into manufacturing it and preparing it for market. The final packaging stages need to protect that investment rather than introduce new risk.
Accurate coding, controlled labelling, reliable traceability and complete documentation all contribute to a smoother path from finished product to supply. When something changes, properly managed relabelling and rework can also help brands correct stock without automatically writing it off.
For Australian pharmaceutical and health brands, choosing a capable secondary packaging provider is therefore an operational decision as much as a packaging decision. The right systems and controls help protect product quality, maintain visibility and keep stock moving through the supply chain.
FAQs
What is secondary pharmaceutical packaging?
Secondary pharmaceutical packaging is packaging or labelling carried out while the medicine remains in its primary container. Depending on the product, it can include cartons, labels, information inserts and other components used to prepare therapeutic goods for supply.
Why is traceability important in pharmaceutical packaging?
Traceability helps businesses identify which batches, packaging materials and components were involved in a production run. This makes it easier to investigate discrepancies, manage product issues and maintain accurate records throughout the supply chain.
Can pharmaceutical products be relabelled or repacked?
Yes. Pharmaceutical products may require relabelling or secondary repacking because of packaging changes, updated approved information or other requirements. The work needs to be carried out under the appropriate controls and regulatory requirements.
What is Release for Supply?
For medicines subject to Australian GMP requirements, Release for Supply is the process in which an authorised person confirms that a batch has been produced and controlled in accordance with the applicable requirements before supply.
What should brands look for in a pharmaceutical secondary packaging provider?
Brands should consider appropriate licensing, relevant pharmaceutical experience, quality assurance systems, traceability, batch reconciliation, coding capabilities, documentation and the ability to manage Release for Supply where required.